Biodesix Inc. (Nasdaq: BDSX) experienced 52% year-over-year core revenue growth for the second quarter of 2022, the company reported Friday.
The life sciences company reported $7.3 million in revenue from its core lung cancer diagnostic tests, up from $4.8 million in the second quarter of 2021. Biodesix brought in $11 million in revenue overall, down 8% year-over-year from $11.9 million.
The company attributed its overall sales decline to an expected decrease in COVID-19 testing revenue, which was down 51% to $3 million from $6.1 million a year ago.
Operating expenses were up 21%, to $18.6 million from $15.3 million.
Biodesix posted a net loss for the quarter of $15.8 million, 39% greater than the $11.3 million it lost in the second quarter of 2021. The company has $28.7 million in cash and equivalents on hand.
This article was first published by BizWest, an independent news organization, and is published under a license agreement. © 2022 BizWest Media LLC.